Candesartan Cilexetil 145040-37-5

.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}


Molecular Weight:

610.66 Candesartan Cilexetil is a specific nonpeptide Ang II receptor (ATR) antagonist and the prodrug of candesartan which is an ATR antagonist with an IC50 of 15 μg/kg.

Biological Activity

Candesartan cilexetil (Atacand) is a specific nonpeptide Ang II receptor (ATR) antagonist and the prodrug of candesartan which is an ATR antagonist with an IC50 of 15 µg/kg. Candesartan cilexetil (Atacand) efficacy is entirely due to its active metabolite candesartan (CV-11794) and is dose-dependent over the range of 1–8 mg and its clinical antihypertensive dose is stated to be around 4 mg/day.

Candesartan cilexetil (Atacand) is administered as a pro-drug that undergoes activation during gastrointestinal absorption. In clinical trials, candesartan cilexetil (Atacand) has produced a dose-dependent effect when given in dosages of 2-32 mg/day. Observed trough-to-peak blood pressure ratios support a once-daily dosage regimen.


The antihypertensive effect of candesartan cilexetil (Atacand) 4-16 mg/day was as great as that of enalapril 10-20 mg/day and amlodipine 5 mg/day and larger than that of losartan potassium 50 mg/day. Adding candesartan cilexetil (Atacand) to hydrochlorothiazide 12.5-25 mg/day and amlodipine 5 mg/day led to enhanced blood-pressure reductions and was well tolerated.

Contact us if you need more details on 145040-37-5. We are ready to answer your questions on packaging, logistics, certification or any other aspects about Candesartan Cilexetil 145040-37-5、145040-37-5 Candesartan Cilexetil. If these products fail to match your need, please contact us and we would like to provide relevant information.

Product Categories : Endocrinology & Hormones > RAAS Inhibitor